Waldenstrom's macroglobulinaemia

被引:12
作者
Johnson, SA [1 ]
Oscier, DG
Leblond, V
机构
[1] Taunton & Somerset Hosp, Taunton TA1 5DA, Somerset, England
[2] Royal Bournemouth Hosp, Bournemouth, Hants, England
[3] Grp Hosp Pitie Salpetriere, F-75634 Paris, France
关键词
Waldenstrom's macroglobulinaemia; diagnosis; treatment; chlorambucil; fludarabine; cladribine; rituximab; transplantation;
D O I
10.1016/S0268-960X(02)00016-4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Waldenstrom's macroglobulinaemia (WM) is most usefully defined as a distinct chronic lymphoproliferative disorder with characteristic marrow morphology and phenotype; although nodal morphology if available will reveal a lymphoplasmacytoid lymphoma, the presence of a significant IgM paraprotein defines the clinical features of the disease. The clonal cell is a B-cell expressing IgM, CD19, and CD20 but not IgD, CD5, CD10 or CD23 and has somatic hypermutation of immunoglobulin heavy chain variable regions consistent with a post-germinal centre origin. Treatment of WM has been dependent on alkylating agents with or without coriticosteroids for many years, supplemented by the use of therapeutic plasmapheresis in the initial stages for patients at risk from the clinical consequences of hyperviscosity. This approach to treatment results in response rates of approximately 60% with a median survival of about 60 months. There is increasing evidence to show that the purine analogues fludarabine and cladribine which are active in the treatment of patients who are resistant to alkylating agents such as chlorambucil may be able to achieve higher response rates when used as initial therapy. A prospective trial is being undertaken to compare fludarabine and chlorambucil as initial treatment; because of the effect of subsequent active treatment on patients who do not respond to the first treatment choice, the long-term outcome may be similar for both groups. Recent advances in therapy include, the use of therapeutic monoclonal antibodies such as rituximab and the use of autologous or allogeneic transplant procedures for selected patients. (C) 2002 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:175 / 184
页数:10
相关论文
共 51 条
[1]   High-dose chemotherapy - High-dose chemotherapy followed by stem cell transplantation in patients with resistant Waldenstrom's macroglobulinemia [J].
Anagnostopoulos, A ;
Dimopoulos, MA ;
Aleman, A ;
Weber, D ;
Alexanian, R ;
Champlin, R ;
Giralt, S .
BONE MARROW TRANSPLANTATION, 2001, 27 (10) :1027-1029
[2]  
[Anonymous], 2001, World Health Organization Classification of Tumours Tumors of Haematopoietic and Lymphoid Tissues
[3]   Cladribine (2-CDA) given as subcutaneous bolus injections is active in pretreated Waldenstrom's macroglobulinaemia [J].
Betticher, DC ;
Schmitz, SFH ;
Ratschiller, D ;
vonRohr, A ;
Egger, T ;
Pugin, P ;
Stalder, M ;
Hess, U ;
Fey, MF ;
Cerny, T .
BRITISH JOURNAL OF HAEMATOLOGY, 1997, 99 (02) :358-363
[4]  
BUSKARD NA, 1977, CAN MED ASSOC J, V117, P135
[5]   Rituximab therapy in Waldenstrom's macroglobulinemia:: Preliminary evidence of clinical activity [J].
Byrd, JC ;
White, CA ;
Link, B ;
Lucas, MS ;
Velasquez, WS ;
Rosenberg, J ;
Grillo-López, AJ .
ANNALS OF ONCOLOGY, 1999, 10 (12) :1525-1527
[6]   WALDENSTROMS MACROGLOBULINEMIA - LONG-TERM RESULTS WITH THE M-2 PROTOCOL [J].
CASE, DC ;
ERVIN, TJ ;
BOYD, MA ;
REDFIELD, DL .
CANCER INVESTIGATION, 1991, 9 (01) :1-7
[7]   SUCCESSFUL DOXORUBICIN THERAPY OF PRIMARY MACROGLOBULINEMIA RESISTANT TO ALKYLATING-AGENTS [J].
CLAMON, GH ;
CORDER, MP ;
BURNS, CP .
AMERICAN JOURNAL OF HEMATOLOGY, 1980, 9 (02) :221-223
[8]   Therapeutic plasma exchange: An update from the Canadian Apheresis Group [J].
Clark, WF ;
Rock, GA ;
Buskard, N ;
Shumak, KH ;
LeBlond, P ;
Anderson, D ;
Sutton, DM .
ANNALS OF INTERNAL MEDICINE, 1999, 131 (06) :453-462
[9]   Cladribine for Waldenstrom's macroglobulinaemia [J].
Delannoy, A ;
Van den Neste, E ;
Michaux, JL ;
Bosly, A ;
Ferrant, A .
BRITISH JOURNAL OF HAEMATOLOGY, 1999, 104 (04) :933-934
[10]   High-dose therapy with autologous haemopoietic stem cell support for Waldenstrom's macroglobulinaemia [J].
Desikan, R ;
Dhodapkar, M ;
Siegel, D ;
Fassas, A ;
Singh, J ;
Singhal, S ;
Mehta, J ;
Vesole, D ;
Tricot, G ;
Jagannath, S ;
Anaissie, E ;
Barlogie, B ;
Munshi, NC .
BRITISH JOURNAL OF HAEMATOLOGY, 1999, 105 (04) :993-996